However, the lower CD4/CD8 ratio and the scarcity of myeloid cells in the GBMwt_lo gliomas could make them more prone to respond to different immunotherapies not only based on the PD-1–PD-L1 axis. The gene discussed is CD4; the disease is central nervous system cancer.